Methacholine inhalation challenge: a shorter, cheaper and safe approach

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology
• Clinical Diagnostics

Background:

• Nonspecific bronchial hyperresponsiveness to agents like methacholine (MCh) is a key asthma indicator.
• Current airway reactivity testing is sensitive but time-consuming and costly.
• There is a need for abbreviated, safe inhalation challenge protocols in clinical settings.

Purpose of the Study:

• To design the shortest, safest inhalation challenge protocol for lung function referral centers.
• To evaluate the feasibility of skipping inhalation steps without compromising data integrity or safety.
• To determine optimal initial doses for abbreviated MCh challenge protocols.

Main Methods:

• Retrospective analysis of 449 patient records from 1996 with baseline FEV1/FVC ratio ≥ 0.7.
• Investigated initial MCh doses and the possibility of skipping concentration steps.
• Calculated provocative dose causing a 20% fall in FEV1 (PD20) via interpolation/extrapolation.

Main Results:

• A three-fold concentration step protocol could be used with minimal impact on outcomes.
• Only 3.3% of patients would have experienced a severe response (FEV1 fall >40%).
• Specific initial doses were identified based on baseline FEV1/FVC ratios (0.073 µmol or 0.219 µmol).

Conclusions:

• A tripling dose MCh inhalation challenge is feasible, faster, cheaper, and safe for referral centers.
• Recommended initial doses vary based on baseline FEV1/FVC ratio.
• Abbreviated protocols used in epidemiology may not be suitable for referral centers.